There’s no denying that biliary tract carcinoma (BTC) presents formidable diagnostic and treatment challenges. That’s why it’s so important for practitioners to stay up to date on the pathophysiology of BTC, as well as current—and even future—first- and second-line treatments. And here to break all those options down for us are Drs. Mitesh Borad and Milind Javle.
Rethinking Approaches to Biliary Tract Carcinoma
Rethinking Approaches to Biliary Tract Carcinoma
Welcome to CME on ReachMD. This activity, titled “Rethinking Approaches to Biliary Tract Carcinoma,” is provided in partnership with TOPEC Global and supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
Before starting this activity, please be sure to review the disclosure statements as well as the learning objectives.
Although uncommon, which biliary tract carcinoma presents formidable diagnostic and treatment challenges, which is why it’s so important to stay up-to-date on the pathophysiology of the disease, the current first- and second-line treatments, and the latest clinical trials. Fortunately, that’s exactly what we’re going to focus on today. I’m
Dr. Mitesh Borad from Mayo Clinic, and I’m today speaking with my colleague, Dr. Milind Javle, from MD Anderson.
Dr. Javle, it’s great to get a chance to speak with you again today.
Thank you, Dr. Borad.
Setting the stage for our viewers today, Dr. Javle, can you quickly highlight what would be included under biliary tract cancers? Is it 1 disease or several diseases together?
So, biliary tract cancer is actually 3 different diseases—gallbladder cancer, intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. These are grouped as one, but they have differing etiologies and, indeed, differing prognosis and sometimes therapies
So, biliary tract cancer is a disease of chronic inflammation—for instance, in gallbladder cancer often related to gallstones, in cholangiocarcinoma related to infections. There are important regional and incidence differences. For instance, in Japan, in China, in East Asia, it’s often associated with hepatitis B infection, in certain areas of the Far East with liver fluke infection. In Europe and the United States, on the other hand, there is a link between biliary tract cancer or cholangiocarcinoma and primary sclerosing cholangitis, as well as intrahepatic cholangiocarcinoma a link with obesity and NASH, or fatty liver.
Now, I recently saw an estimate that more than 65% of patients with a diagnosis of BTC present with nonresectable disease and that their prognosis is typically poor. So, in your opinion, Dr. Javle, what are the signs and symptoms of BTCs, and why are they so difficult to diagnose at an earlier stage?
So, biliary tract cancers, as you appropriately highlighted, are often diagnosed at an advanced, unresectable stage. Let me give you an example of intrahepatic cholangiocarcinoma. These tumors can grow to a considerable size before they cause biliary tract obstruction, and often I discovered, due to ill-defined abdominal discomfort or alteration in liver function tests, due to the uncommon nature of this disease, often patients are seen by their family practitioners, and this is not the most common or the most frequent diagnosis because these symptoms can mimic several non-cancer diagnoses as well. So, as a consequence, these diseases are often discovered quite late when surgery becomes impossible. I believe that is an important factor why the prognosis of biliary tract cancer is so low.
Continuing on to the treatments for biliary tract cancers, can you highlight what are the current standard first- and second-line treatments in this disease?
So, the first-line treatment for advanced unresectable biliary tract cancer is based on the ABC-02 trial from the United Kingdom, now almost 10 years ago, and that is gemcitabine and cisplatin. The second-line treatment approach is not yet defined. ABC-06 trial, which tested the regimen of FOLFOX versus placebo, will be discussed at the ASCO 2019 meeting. Hopefully, that creates a new standard in treatment. In terms of surgical resection, as you mentioned earlier, very few patients, less than 20%, are appropriate for surgical resection. Clearly, if patients have localized disease, surgery is the only potential option that can provide cure, so if the patient is diagnosed at an earlier stage in either biliary tract cancer, then surgery sometimes followed by additional treatment is the standard of care today.
For those joining us, this is CME on ReachMD. I’m Dr. Milind Javle, and today I’m speaking with Dr. Mitesh Borad from Mayo Clinic about biliary tract cancer, or BTCs.
So, first of all, I’d like to get your opinion of identifying the greatest unmet needs for patients diagnosed with BTC. Where are we struggling the most for these patients? Can you discuss the perspective of the most pressing unmet needs in diagnosis and treatment for BTCs?
Yeah, I’ll quickly highlight. With diagnosis, it is difficult to diagnose these patients early enough, so little things, say, like liquid biopsy become important in that aspect. With regards to treatment, you highlighted that the current standard approaches are cytotoxic chemotherapies. While they seem to help patients live longer, the number of patients having durable responses is quite low, and this is where I think approaches such as immunotherapy will really have a big role. Like other tumors, the immune checkpoint inhibitors have been evaluated. This includes things such as nivolumab and pembrolizumab. Unfortunately, the response rates have sort of been in the less than 10% range in larger studies, albeit in the patients where these do occur, relatively durable.
There are some newer agents that appear to be very exciting. One that I would want to highlight is M7824, also known as Bintrafusp alpha. This is a very unique molecule with bifunctional capabilities where 1 domain binds to PD-L1 and the second domain is TGF beta receptor 2 extracellular domain that binds to TGF beta, which is thought to be an immunosuppressive moiety in the tumor microenvironment. In early studies it has shown response rate of about 20%. However, the key thing here is that these responses are quite durable, lasting anywhere from 8 to 14 months thus far. Immunotherapy, I feel, is really the area where a lot of investigation will occur in this disease, and we hope to see results from larger, later-stage trials with this types of drugs.
So, Dr. Javle, as we come to a close here, is there anything you would like to highlight for our viewers today?
Thank you, Dr. Borad. BTC is really an exciting area of research, particularly now, whereas there were very, very few trials even as recently at 10 years ago. Areas that I would want to highlight are cytotoxic chemotherapy. There are 2 important trials that I would highlight in Europe for FOLFIRINOX, which is gemcitabine and cisplatin. It’s a phase II randomized study. Here in the US, based on some work that was done with you at Mayo Clinic, and MD Anderson, gemcitabine cisplatin abraxane, a 3-drug regimen, is being investigated in a phase III trial against gemcitabine and cisplatin.
A particularly exciting area is within the realms of targeted therapy. So, as you know, there are multiple actionable mutations in these cancers. I just highlight 2 with IDH1 mutations where a phase III trial has been completed with AG-120. There are at least 4 ongoing trials with FGFR inhibitors, and we will get the readout very soon. And as you mentioned earlier, there are immunotherapy trials in this space, such as the exciting trial with M7824.
And my last question for you, Dr. Borad: Are there any takeways from what you and I talked about earlier or maybe something we haven’t yet covered that you want to share for the audience?
I think we should just summarize that while these are uncommon cancers, there seems to be a lot going on in terms of clinical trials, whether it be immunotherapy, precision medicine, or even standard cytotoxics, and it has become a robust environment for investigation; and hopefully, these will lead to advances that will help patients.
Well, unfortunately, it’s that time to draw this program to close, but it’s been great discussing biliary tract cancers together. Thank you for joining me, Dr. Borad.
It’s been great fun discussing biliary tract cancers with you, Dr. Javle, today. We thank our viewers for their attention and hope to speak soon again.
This has been CME on ReachMD. The preceding activity was brought to you by TOPEC Global. To receive your free CME credit or to download this activity, please visit ReachMD.com/CME. Be part of the knowledge.
In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Mitesh J. Borad, MD
Director, Liver and Biliary Cancer Research Program
Dr. Borad has disclosed consulting fees for Merck, and contracted research for Agios, AstraZeneca, Basil Pharmaceuticals, Celgene, EMD Serono, Halozyme, Inc., Incyte, Que Oncology, Senhwa Biosciences, and Taiho Oncology.
Milind Javle, MD
The University of Texas MD Anderson Cancer Center
Department of Gastrointestinal Medical OncologyDivision of Cancer Medicine
Dr. Javle has disclosed he receives honoraria from Merck, Seattle Genetics, and Taiho; research and grant funding from Arqule, Lilly, Meclun, Novartis, and QED; and is a consultant for EDO, More Health, and Origimed.
- Sean T. Barrett has nothing to disclose.
- Ann Early has nothing to disclose.
- Barry A. Fiedel, PhD has nothing to disclose.
- Brian McDonough, MD has nothing to disclose.
- John Pirovitz has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Discuss the pathophysiology and burden of disease of biliary tract carcinomas (BTC).
- Analyze current therapeutic approaches to BTC, especially as related to late stage disease and unacceptably poor patient outcomes.
This activity is designed to meet the educational needs of practicing Oncologists, Medical Oncologists and Hematologists.
The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org.
TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”.
Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.